311 related articles for article (PubMed ID: 30442649)
21. Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay.
Bi YA; Jordan S; King-Ahmad A; West MA; Varma MVS
Clin Pharmacol Ther; 2024 Jun; 115(6):1336-1345. PubMed ID: 38404228
[TBL] [Abstract][Full Text] [Related]
22. Glycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic organic anion-transporting polypeptide 1B1/1B3.
Dong J; Olaleye OE; Jiang R; Li J; Lu C; Du F; Xu F; Yang J; Wang F; Jia W; Li C
Br J Pharmacol; 2018 Sep; 175(17):3486-3503. PubMed ID: 29908072
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations.
Yu J; Wang Y; Ragueneau-Majlessi I
Drug Metab Dispos; 2022 Jan; 50(1):1-7. PubMed ID: 34620694
[TBL] [Abstract][Full Text] [Related]
24. Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
Kalluri HV; Kikuchi R; Coppola S; Schmidt J; Mohamed MF; Bow DAJ; Salem AH
Clin Transl Sci; 2021 Jan; 14(1):373-381. PubMed ID: 33048456
[TBL] [Abstract][Full Text] [Related]
25. Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions.
Mochizuki T; Zamek-Gliszczynski MJ; Yoshida K; Mao J; Taskar K; Hirabayashi H; Chu X; Lai Y; Takashima T; Rockich K; Yamaura Y; Fujiwara K; Mizuno T; Maeda K; Furihata K; Sugiyama Y; Kusuhara H
Clin Pharmacol Ther; 2022 Jun; 111(6):1315-1323. PubMed ID: 35292967
[TBL] [Abstract][Full Text] [Related]
26. Linking organic anion transporting polypeptide 1B1 and 1B3 (OATP1B1 and OATP1B3) interaction profiles to hepatotoxicity - The hyperbilirubinemia use case.
Kotsampasakou E; Escher SE; Ecker GF
Eur J Pharm Sci; 2017 Mar; 100():9-16. PubMed ID: 28063966
[TBL] [Abstract][Full Text] [Related]
27. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
28. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
[TBL] [Abstract][Full Text] [Related]
29. [Quantitative assessment of the risk of OATP1B1/1B3-mediated drug-drug interactions].
Mori D; Maeda K; Kusuhara H
Nihon Yakurigaku Zasshi; 2019; 154(4):210-216. PubMed ID: 31597901
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1.
Elsby R; Hare V; Neal H; Outteridge S; Pearson C; Plant K; Gill RU; Butler P; Riley RJ
Drug Metab Dispos; 2019 Jan; 47(1):1-8. PubMed ID: 30348903
[TBL] [Abstract][Full Text] [Related]
31. Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.
Chang M; Bathena S; Christopher LJ; Shen H; Roy A
Cancer Chemother Pharmacol; 2022 Mar; 89(3):383-392. PubMed ID: 35147740
[TBL] [Abstract][Full Text] [Related]
32. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
Wang Q; Zheng M; Leil T
CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
[TBL] [Abstract][Full Text] [Related]
33. Multiple circulating saponins from intravenous ShenMai inhibit OATP1Bs in vitro: potential joint precipitants of drug interactions.
Olaleye OE; Niu W; Du FF; Wang FQ; Xu F; Pintusophon S; Lu JL; Yang JL; Li C
Acta Pharmacol Sin; 2019 Jun; 40(6):833-849. PubMed ID: 30327544
[TBL] [Abstract][Full Text] [Related]
34. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
[TBL] [Abstract][Full Text] [Related]
36. Variability in In Vitro OATP1B1/1B3 Inhibition Data: Impact of Incubation Conditions on Variability and Subsequent Drug Interaction Predictions.
McFeely SJ; Ritchie TK; Ragueneau-Majlessi I
Clin Transl Sci; 2020 Jan; 13(1):47-52. PubMed ID: 31468718
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
Gertz M; Cartwright CM; Hobbs MJ; Kenworthy KE; Rowland M; Houston JB; Galetin A
Pharm Res; 2013 Mar; 30(3):761-80. PubMed ID: 23179780
[TBL] [Abstract][Full Text] [Related]
38. Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
Schilling U; Dingemanse J; Voors-Pette C; Romeijn C; Dogterom P; Ufer M
Clin Transl Sci; 2020 Sep; 13(5):886-890. PubMed ID: 32166864
[TBL] [Abstract][Full Text] [Related]
39. Preincubation Time-Dependent, Long-Lasting Inhibition of Drug Transporters and Impact on the Prediction of Drug-Drug Interactions.
Nozaki Y; Izumi S
Drug Metab Dispos; 2023 Sep; 51(9):1077-1088. PubMed ID: 36854606
[TBL] [Abstract][Full Text] [Related]
40. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
Kosloski MP; Bow DAJ; Kikuchi R; Wang H; Kim EJ; Marsh K; Mensa F; Kort J; Liu W
J Pharmacol Exp Ther; 2019 Aug; 370(2):278-287. PubMed ID: 31167814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]